broker's report

Broker's Calls

JPM initiates 'overweight' on TDCX as it is a profitable compounder

JPM starts TDCX off with an 'overweight' rating as it is a profitable play on the growth of the new economy.

Broker's Calls

StarHub gets an upgrade as it rides on reopening tailwinds

Maybank Securities gives StarHub an upgrade as it is well positioned to ride on the reopening.
Is Grab still grabworthy? - THE EDGE SINGAPORE

Broker's Calls

Is Grab still grabworthy?

Following Grab's investor day, analysts seem to be able to see the light at the end of the tunnel for Grab.
Robust tourism demand keeps SIA a 'buy': KGI Research - THE EDGE SINGAPORE

Broker's Calls

Robust tourism demand keeps SIA a 'buy': KGI Research

The resumption of tourism and large events in Singapore is expected to give SIA a much needed boost.
FCT's increased stake in Waterway Point a positive in analysts' books - THE EDGE SINGAPORE

Broker's Calls

FCT's increased stake in Waterway Point a positive in analysts' books

FCT's latest stake increment in Waterway Point is a seen as a good move by analysts.

Broker's Calls

Megachem kept at 'buy' on 1H earnings beat

With 1H earnings coming in better than expected and a newly launched warehouse, SAC Capital is keeping 'buy' on Megachem.
Uni-Asia kept at 'buy' on stellar 1H earnings and positive outlive - THE EDGE SINGAPORE

Broker's Calls

Uni-Asia kept at 'buy' on stellar 1H earnings and positive outlook

With a record 1HFY2022 results and all-time high interim dividend, PhillipCapital is keeping its 'buy' call on Uni-Asia.

Broker's Calls

UOBKH is focusing on REITs with reopening plays

UOBKH's top S-REIT picks include: FCT, FEHT and LREIT.

Broker's Calls

Likely a decent start to FY2023 for Singtel: CGS-CIMB

Singtel is expected to see a q-o-q improvement in its upcoming 1Q results.

Broker's Calls

'Add' Hyphens Pharma as it moves on to its next phase of growth

CGS-CIMB Research is betting on Hyphens Pharma's next phase of growth.
×